Hormone Receptor Positive HER-2 Negative Breast Cancer Clinical Trials

13 clinical trials for Hormone Receptor Positive HER-2 Negative Breast Cancer across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer — RECRUITING · PHASE2
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer — RECRUITING · PHASE1
• VS-6766+Abema+Fulv in Met HR+/HER- BC — RECRUITING · PHASE1
• Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer — RECRUITING
• Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer — RECRUITING · PHASE2
• Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study — RECRUITING
• TCb vs EC-T in High Risk ER+/HER2- Breast Cancer — RECRUITING · PHASE3
• Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC — NOT_YET_RECRUITING · PHASE1
• A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer — NOT_YET_RECRUITING · PHASE2
• A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib — COMPLETED
• Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer — COMPLETED · PHASE2

Refine this search